http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9814205-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e13fdcd619e15c320d642de7703fffa7
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-605
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-001164
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-001151
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-001106
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00
filingDate 1997-09-30-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8033ef3518cc2192922b16af320e55a3
publicationDate 1998-04-09-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber WO-9814205-A1
titleOfInvention Cancer therapy using an oncogene product and a foreign mhc molecule
abstract A cancer immunogen comprises foreign MHC molecules and additionally one or more oncognes (or constructs that will produce an antigenic region thereof) which can be used to immunise against tumours containing the same or similar oncogenes. Where pathogen-free allogeneic cells are used, it may not be necessary to kill the vaccine before it is administered. The efficacy of the vaccine may be enhanced if the cells also contain immunoenhancing molecules, tumour antigens, or third-party antigens. Cell vaccines containing oncongens can be standardised and used to treat (risk of) specific cancers where there are analogous oncongenes in the tumour or pre-cancerous cells. A panel of such cells covering different oncogenes may be used. The vaccines can be used to immunise prophylactically, in conjuction with other therapy, post-surgery or on their own.
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7402306-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9186418-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7670611-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AU-763485-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-0066153-A1
priorityDate 1996-09-30-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9003183-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9421287-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9724123-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9531107-A1
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID2733531
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226405934
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID231224
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5746
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID136084913
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395874
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395875

Total number of triples: 32.